Cserni Gábor, Vörös András, Liepniece-Karele Inta, Bianchi Simonetta, Vezzosi Vania, Grabau Dorthe, Sapino Anna, Castellano Isabella, Regitnig Peter, Foschini Maria Pia, Zolota Vassiliki, Varga Zsuzsanna, Figueiredo Paulo, Decker Thomas, Focke Cornelia, Kulka Janina, Kaya Handan, Reiner-Concin Angelika, Amendoeira Isabel, Callagy Grace, Caffrey Emer, Wesseling Jelle, Wells Clive
Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary; Department of Pathology, University of Szeged, Hungary.
Department of Pathology, University of Szeged, Hungary.
Breast. 2014 Jun;23(3):259-63. doi: 10.1016/j.breast.2014.02.003. Epub 2014 Mar 7.
The Ki67 labelling index (LI - proportion of staining cells) is widely used to reflect proliferation in breast carcinomas. Several cut-off values have been suggested to distinguish between tumours with low and high proliferative activity. The aim of the current study was to evaluate the distribution of Ki67 LIs in breast carcinomas diagnosed at different institutions by different pathologists using the method reflecting their daily practice. Pathologists using Ki67 were asked to provide data (including the LI, type of the specimen, receptor status, grade) on 100 consecutively stained cases, as well as details of their evaluation. A full dataset of 1709 carcinomas was collected from 19 departments. The median Ki67 LI was 17% for all tumours and 14% for oestrogen receptor-positive and HER2-negative carcinomas. Tumours with higher mitotic counts were associated with higher Ki67 LIs. Ki67 LIs tended to cluster around values ending with 5 or 0 both in cases where the values were obtained by counting the proportion of stained tumour cell nuclei and those where the values were obtained by estimation. On the basis of the distribution pattern described, some currently used Ki67 LI cut off values are not realistic, and it is proposed to select more realistic values ending with 0 or 5.
Ki67标记指数(LI,即染色细胞的比例)被广泛用于反映乳腺癌的增殖情况。已经提出了几个临界值来区分增殖活性低和高的肿瘤。本研究的目的是评估不同机构的不同病理学家采用反映其日常实践的方法诊断的乳腺癌中Ki67 LI的分布情况。要求使用Ki67的病理学家提供100例连续染色病例的数据(包括LI、标本类型、受体状态、分级)以及他们的评估细节。从19个科室收集了1709例癌的完整数据集。所有肿瘤的Ki67 LI中位数为17%,雌激素受体阳性且人表皮生长因子受体2阴性的癌为14%。有丝分裂计数较高的肿瘤与较高的Ki67 LI相关。无论是通过计数染色肿瘤细胞核的比例还是通过估计获得Ki67 LI值的情况,Ki67 LI值都倾向于聚集在以5或0结尾的值周围。基于所描述的分布模式,一些目前使用的Ki67 LI临界值不切实际,建议选择以0或5结尾的更实际的值。